Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

PTC Therapeutics, Inc. - Common Stock (NQ: PTCT )

51.82 +2.15 (+4.33%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about PTC Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
UniQure Stock Nearly Doubles After Striking A Deal With The FDA For Huntington's Drug
The company is testing a gene therapy for Huntington's disease and could soon seek an accelerated approval. 
Via Investor's Business Daily
Exposures Product Safety
Novartis Touts Encouraging Data From Late-Stage Study For Fabhalta In Rare Type Of Blood Disorder
Novartis reports positive Phase 3B results for Fabhalta in PNH patients, highlighting improved hemoglobin levels and consistent safety profile after 24 weeks. 
Via Benzinga
Bank of America To Rally More Than 21%? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
PTC Therapeutics Inks Licensing Pact With Novartis Worth Up To ~$3 Billion For Huntington's Program
PTC Therapeutics partners with Novartis for its PTC518 Huntington's program in a deal valued up to $2.9 billion, including milestones and royalties. 
Via Benzinga
XPeng, NovoCure, Merus, Gap And Other Big Stocks Moving Higher On Monday
Via Benzinga
Earnings Preview For PTC Therapeutics
Via Benzinga
Recap: PTC Therapeutics Q4 Earnings
Via Benzinga
Earnings Scheduled For February 29, 2024
Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million. 
Via Benzinga
PTC Therapeutics Scores A $2.9 Billion Novartis Deal And Hits Profit-Taking Zone
The deal focuses on the company's treatment for Huntington's disease. 
Via Investor's Business Daily
PTC Therapeutics Ends Utreloxastat Development After Rare Neurodegenerative Disease Trial Misses Goal, Analyst Maintains Outperform With Focus On Sepiapterin, Huntington's Programs
PTC Therapeutics halts Utreloxastat development after ALS trial disappoints. Analysts highlight promising pipeline, including Huntington's and PKU programs. 
Via Benzinga
FDA Grants Conditional Approval For PTC Therapeutics' Gene Therapy As First Ever With Direct Administration In Brain
PTC Therapeutics' Kebilidi gains FDA accelerated approval as the first brain-administered gene therapy in the U.S. for AADC deficiency treatment. 
Via Benzinga
Exposures Product Safety
3 Top Stocks That Could Still Rocket Higher in 2024
Upcoming Food and Drug Administration decisions could push these stocks through the roof. 
Via The Motley Fool
PTC Therapeutics Stock Earns RS Rating Upgrade To 83
The Relative Strength (RS) Rating for PTC Therapeutics stock climbed into a new percentile Monday, with a rise from 80 to 83. 
Via Investor's Business Daily
Earnings Preview: PTC Therapeutics
Via Benzinga
PTCT Stock Earnings: PTC Therapeutics Misses EPS, Beats Revenue for Q2 2024
PTCT stock results show that PTC Therapeutics missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Nike, Accolade And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Via Benzinga
PTC Therapeutics Tumbles After European Regulators Reject Its Drug — Again
The company plans to ask for another re-examination for its drug in Europe. 
Via Investor's Business Daily
Asana, Clover Health Investments, Hertz Global And Other Big Stocks Moving Higher On Friday
Via Benzinga
PTC Therapeutics Says FDA Lifts Clinical Hold On Investigational Study In Patients With Rare Weak Nerve Cell Disorder
PTC Therapeutics released interim results from its Phase 2 PIVOT-HD study on PTC518 for Huntington's disease. The FDA has lifted the partial clinical hold on the program. 
Via Benzinga
Exposures Product Safety
The 3 Most Undervalued Biotech Stocks to Buy in June 2024
https://seekingalpha.com/news/4111624-goldman-sachs-raises-obesity-drug-market-estimate 
Via InvestorPlace
Why Virios Therapeutics Shares Are Trading Lower By Around 48%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
European Commission Requests Reevaluation Of Opinion On PTC Therapeutics' Duchenne Dystrophy Drug; Pauses Annual Guidance
PTC Therapeutics announced that the European Commission has asked the CHMP to re-evaluate its negative opinion on the renewal of Translarna's conditional marketing authorization, keeping it available... 
Via Benzinga
Overseas Shipholding, Micron, Squarespace, Incyte And Other Big Stocks Moving Higher On Monday
Via Benzinga
PTC Therapeutics Stock Soars As Its Biggest Drug 'Lives To Fight Another Day'
The EC is asking its committee to reexamine its decision on Translarna. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
PTC Therapeutics Stock Sees IBD RS Rating Climb To 72
PTC Therapeutics stock saw a positive improvement to its Relative Strength (RS) Rating on Wednesday, rising from 61 to 72. 
Via Investor's Business Daily
PTCT Stock Earnings: PTC Therapeutics Beats EPS, Beats Revenue for Q1 2024
PTCT stock results show that PTC Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Cooper Companies Reports Upbeat Results, Joins Dell, NetApp, Tidewater And Other Big Stocks Moving Higher On Friday
U.S. stocks were higher, with the Nasdaq Composite gaining around 0.5% on Friday. 
Via Benzinga
Topics Stocks
Exposures US Equities
1 of Sarepta Therapeutics' Competitors Just Got Hammered. Will It Help the Stock?
Bad news for one player does not always equal good news for another. 
Via The Motley Fool
PTC Therapeutics Flashes A Bearish Sign After European Officials Reject DMD Drug
European regulators will likely force PTC Therapeutics to pull its drug, Translarna, from the market. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.